tiprankstipranks
Advertisement
Advertisement

VALN Stock Latest News

Valneva Tightens 2026 Guidance and Restructures as Lyme Vaccine Nears Regulatory Filings
Company AnnouncementsValneva Tightens 2026 Guidance and Restructures as Lyme Vaccine Nears Regulatory Filings
7d ago
6K
VALN
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
10d ago
VALN
Valneva Sets May 13 Date to Present First-Quarter 2026 Results
PremiumCompany Announcements
Valneva Sets May 13 Date to Present First-Quarter 2026 Results
16d ago
6K
VALN
Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone
PremiumCompany Announcements
Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone
20d ago
6K
VALN
Valneva downgraded to Sell from Neutral at Goldman Sachs
PremiumThe Fly
Valneva downgraded to Sell from Neutral at Goldman Sachs
29d ago
VALN
Valneva price target lowered to $11 from $13 at Guggenheim
PremiumThe FlyValneva price target lowered to $11 from $13 at Guggenheim
1M ago
VALN
Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
Premium
Company Announcements
Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
2M ago
6K
VALN
Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate
Premium
Company Announcements
Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate
2M ago
6K
VALN
Jefferies says Valneva stock weakness presents buying opportunity
PremiumThe Fly
Jefferies says Valneva stock weakness presents buying opportunity
2M ago
VALN
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
PremiumMarket News
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
2M ago
PFE
VALN
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
PremiumThe Fly
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
2M ago
PFE
VALN
Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
PremiumCompany Announcements
Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
2M ago
6K
VALN
Elaris FlexCo secures exclusive global license from Valneva
PremiumThe FlyElaris FlexCo secures exclusive global license from Valneva
2M ago
VALN
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
VALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
VALN
Valneva Sets March 18 Date to Release Full-Year 2025 Results
Premium
Company Announcements
Valneva Sets March 18 Date to Release Full-Year 2025 Results
2M ago
6K
VALN
Valneva Ramps Up Investor Outreach Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva Ramps Up Investor Outreach Ahead of Key Lyme Vaccine Data
3M ago
6K
VALN
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
3M ago
6K
VALN
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
PremiumCompany Announcements
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
3M ago
6K
VALN
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
PremiumCompany Announcements
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
4M ago
6K
VALN
Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
PremiumCompany AnnouncementsValneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
4M ago
6K
VALN
Valneva withdraws BLA, IND application for Ixchiq in U.S.
Premium
The Fly
Valneva withdraws BLA, IND application for Ixchiq in U.S.
4M ago
VALN
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
Premium
Company Announcements
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
4M ago
6K
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >